It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice. Review the most recent clinical trial data supporting these strategies, including outcomes across biomarker-defined subgroups. Faculty will discuss optimal patient selection, sequencing considerations, and management of treatment-related toxicities, giving learners a clearer understanding of the role of established maintenance approaches in contemporary ovarian cancer care.